RNAC
Cartesian Therapeutics, Inc. NASDAQ Listed Jun 22, 2016$9.63
After hrs
$9.64
+0.10%
Mkt Cap $250.1M
52w Low $5.84
47.8% of range
52w High $13.77
50d MA $7.20
200d MA $7.70
P/E (TTM)
-1.9x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.1x
ROE
103.2%
P/FCF
-3.2x
RSI (14)
62.50
ATR (14)
$1.13
Beta
0.56
50d MA
$7.20
200d MA
$7.70
Avg Volume
358.2K
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
65 Grove Street · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.84 | -1.46 | -73.8% | 6.22 | -0.3% | +0.0% | +11.4% | +6.6% | +12.9% | -2.2% | — |
| Mar 9, 2026 | AMC | -0.82 | -1.38 | -68.3% | 9.02 | +0.9% | -5.2% | -3.4% | -1.7% | -9.0% | -0.8% | — |
| Nov 6, 2025 | AMC | -0.81 | -1.38 | -70.4% | 7.55 | -0.9% | +4.2% | -8.0% | +0.8% | +3.8% | -4.6% | — |
| Aug 7, 2025 | AMC | -0.76 | 0.50 | +165.8% | 10.54 | -0.3% | -0.1% | +5.4% | +2.1% | +3.4% | -2.4% | — |
| May 8, 2025 | AMC | -0.61 | -0.68 | -11.5% | 10.42 | -0.4% | -5.0% | +5.5% | -2.3% | -2.2% | +4.5% | — |
| Mar 20, 2025 | AMC | -0.78 | -0.59 | +24.4% | 15.93 | +2.8% | +0.8% | -0.7% | -0.1% | -6.5% | -3.5% | — |
| Nov 7, 2024 | AMC | -0.78 | -0.69 | +11.5% | 20.78 | +1.6% | -0.1% | -4.7% | -14.4% | +1.1% | -0.6% | — |
| Aug 8, 2024 | AMC | -1.07 | 0.54 | +150.5% | 12.87 | +0.3% | +3.9% | -5.0% | +7.6% | -4.3% | +10.5% | — |
| May 8, 2024 | AMC | -0.81 | -1.97 | -143.2% | 23.25 | -2.2% | -6.0% | -3.2% | +1.3% | +15.4% | +7.7% | — |
| Mar 7, 2024 | AMC | -0.30 | -2.40 | -700.0% | 19.31 | +2.0% | -0.6% | -0.2% | -8.0% | -6.5% | -2.7% | — |
| Nov 13, 2023 | AMC | -2.10 | -2.40 | -14.3% | 26.44 | -8.5% | +21.4% | -9.4% | +8.3% | +1.9% | +4.7% | — |
| Aug 17, 2023 | AMC | -0.09 | -0.07 | +22.2% | 33.60 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Wedbush | Maintains | Outperform → Outperform | — | $6.22 | $6.20 | -0.3% | +0.0% | +11.4% | +6.6% | +12.9% | -2.2% |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $9.02 | $9.10 | +0.9% | -5.2% | -3.4% | -1.7% | -9.0% | -0.8% |
| Mar 9 | Needham | Maintains | Buy → Buy | — | $6.85 | $6.55 | -4.4% | +31.7% | -5.2% | -3.4% | -1.7% | -9.0% |
| Mar 9 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $6.85 | $6.55 | -4.4% | +31.7% | -5.2% | -3.4% | -1.7% | -9.0% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $8.12 | $8.07 | -0.6% | +1.0% | -11.3% | +5.4% | -0.3% | -3.7% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.62 | $7.55 | -0.9% | -6.2% | +0.0% | +1.3% | +2.6% | -1.5% |
| Nov 14 | BTIG | Maintains | Buy → Buy | — | $7.23 | $7.50 | +3.7% | +3.2% | -1.1% | +3.3% | -6.2% | +0.0% |
| May 8 | Needham | Maintains | Buy → Buy | — | $10.15 | $10.26 | +1.1% | +2.7% | -5.0% | +5.5% | -2.3% | -2.2% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $9.52 | $9.34 | -1.9% | +19.3% | -8.8% | +3.0% | +21.8% | -7.9% |
| Apr 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.52 | $9.34 | -1.9% | +19.3% | -8.8% | +3.0% | +21.8% | -7.9% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.61 | $16.58 | -0.2% | -4.9% | -8.6% | +1.1% | +5.9% | +3.0% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $17.48 | $17.13 | -2.0% | -5.0% | -4.9% | -8.6% | +1.1% | +5.9% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.42 | $19.32 | -0.5% | +2.9% | -3.8% | +0.8% | -0.4% | +3.0% |
| Jan 27 | Needham | Maintains | Buy → Buy | — | $19.20 | $19.10 | -0.5% | +1.1% | +2.9% | -3.8% | +0.8% | -0.4% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $16.84 | $16.56 | -1.7% | +8.8% | -1.7% | +5.2% | -0.1% | +1.9% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.08 | $20.68 | +3.0% | +9.6% | +4.6% | +9.3% | -2.8% | -6.6% |
| Dec 3 | Needham | Maintains | Buy → Buy | — | $19.57 | $19.80 | +1.2% | +2.6% | +9.6% | +4.6% | +9.3% | -2.8% |
| Nov 25 | Needham | Maintains | Buy → Buy | — | $18.87 | $19.42 | +2.9% | -5.1% | +4.1% | -4.0% | +5.1% | +3.9% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.78 | $21.11 | +1.6% | -0.1% | -4.7% | -14.4% | +1.1% | -0.6% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $20.78 | $21.11 | +1.6% | -0.1% | -4.7% | -14.4% | +1.1% | -0.6% |
| Oct 16 | Needham | Maintains | Buy → Buy | — | $20.63 | $20.78 | +0.7% | +6.1% | -0.8% | +5.4% | -1.4% | -1.7% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.07 | $16.00 | -0.4% | +4.2% | -4.4% | +3.9% | -6.0% | +5.8% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.12 | $13.05 | -0.5% | +2.6% | +4.3% | -7.5% | +1.1% | +13.3% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.37 | $13.33 | -0.3% | -5.0% | +7.6% | -4.3% | +10.5% | -1.6% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $12.87 | $12.91 | +0.3% | +3.9% | -5.0% | +7.6% | -4.3% | +10.5% |
| Jul 8 | Needham | Maintains | Buy → Buy | — | $16.97 | $16.87 | -0.6% | -0.9% | -0.2% | +0.8% | +5.0% | -0.1% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.77 | $16.16 | +2.5% | +11.7% | -3.7% | -0.9% | -0.2% | +0.8% |
| Jul 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.77 | $16.16 | +2.5% | +11.7% | -3.7% | -0.9% | -0.2% | +0.8% |
| Jul 2 | Oppenheimer | Downgrade | Outperform → Peer Perform | — | $24.27 | $17.97 | -26.0% | -35.0% | +11.7% | -3.7% | -0.9% | -0.2% |
| Jul 1 | Needham | Maintains | Buy → Buy | — | $27.01 | $26.51 | -1.9% | -10.1% | -35.0% | +11.7% | -3.7% | -0.9% |
| Jun 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $22.80 | $22.36 | -1.9% | +1.1% | +4.4% | +2.9% | +15.2% | -5.3% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.29 | $26.82 | -1.7% | -14.5% | -6.7% | +5.2% | -0.4% | +1.1% |
| Jun 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.29 | $28.77 | -1.8% | -6.8% | -14.5% | -6.7% | +5.2% | -0.4% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.46 | $25.84 | +1.5% | +0.0% | -3.5% | +15.0% | +2.6% | +8.4% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.25 | $22.73 | -2.2% | -6.0% | -3.2% | +1.3% | +15.4% | +7.7% |
| May 8 | Needham | Maintains | Buy → Buy | — | $23.21 | $23.00 | -0.9% | +0.2% | -6.0% | -3.2% | +1.3% | +15.4% |
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.26 | $20.26 | +11.0% | +12.8% | +0.6% | +0.9% | +0.6% | +4.6% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $13.99 | $13.44 | -3.9% | +16.7% | +10.5% | +7.5% | -2.1% | -1.2% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.41 | $16.80 | -3.5% | +8.9% | +13.8% | +7.0% | -8.5% | +1.5% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.20 | $19.05 | -0.8% | -0.2% | -8.0% | -6.5% | -2.7% | +8.4% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.17 | $21.23 | +5.3% | +4.1% | -8.0% | -0.6% | -0.2% | -8.0% |
| Aug 18 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $33.60 | $32.10 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% |
| Aug 18 | Needham | Maintains | Buy → Buy | — | $33.60 | $32.10 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% |
| Aug 18 | Mizuho | Maintains | Buy → Buy | — | $33.60 | $32.10 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.60 | $32.10 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% |
| Mar 22 | Mizuho | Maintains | Buy → Buy | — | $37.80 | $37.80 | +0.0% | +11.9% | +2.8% | -2.8% | -5.7% | -3.8% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.80 | $37.80 | +0.0% | +11.9% | +2.8% | -2.8% | -5.7% | -3.8% |
| Jan 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $52.80 | $53.85 | +2.0% | +0.6% | +3.4% | +1.6% | -1.1% | -0.5% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.20 | $39.30 | +5.6% | +1.6% | +0.0% | +11.1% | -5.0% | +0.8% |
| Jun 14 | Needham | Maintains | Buy → Buy | — | $33.60 | $33.00 | -1.8% | -6.2% | +9.5% | +16.5% | -7.5% | +1.6% |
No insider trades available.
8-K
Cartesian Therapeutics, Inc. -- 8-K Filing
Jun 17
8-K · 7.01
! Medium
Cartesian Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 9
8-K · 5.02
!!! Very High
Cartesian Therapeutics, Inc. -- 8-K 5.02: Executive Change
Cartesian Therapeutics' Chief Medical Officer Milos Miljkovic resigned May 22, 2026, requiring the company to negotiate a separation agreement, potentially creating leadership continuity risks for the biopharmaceutical firm.
May 26
8-K
Cartesian Therapeutics, Inc. -- 8-K Filing
Cartesian Therapeutics reported Q1 2026 results and highlighted Descartes-08 as a promising late-stage cell therapy candidate with potential to address unmet autoimmune disease treatment needs through durable response.
Apr 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
RNAC's executive change signals potential strategic shifts and management uncertainty that could impact operational direction and investor confidence in near-term performance.
Mar 30
8-K
Cartesian Therapeutics, Inc. -- 8-K Filing
Cartesian Therapeutics (RNAC) expects 2026 to be transformative as it advances its Descartes-08 cell therapy candidate across multiple autoimmune disease indications in late-stage clinical development.
Mar 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 799,743 | $5M | Reduced | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 407,597 | $3M | New | Mar 2026 |
| 3 | Millennium Management | 284,317 | $2M | Added | Mar 2026 |
| 4 | Marshall Wace, Llp | 251,115 | $2M | Added | Mar 2026 |
| 5 | Privium Fund Management B.v. | 179,114 | $1M | Added | Mar 2026 |
| 6 | Two Sigma Investments, Lp | 167,313 | $1M | Added | Mar 2026 |
| 7 | Ubs Group Ag | 136,840 | $842K | Added | Mar 2026 |
| 8 | Citadel Advisors Llc | 110,128 | $677K | Added | Mar 2026 |
| 9 | Northern Trust Corp | 91,992 | $566K | Added | Mar 2026 |
| 10 | Aqr Capital Management Llc | 84,020 | $517K | New | Mar 2026 |
| 11 | Renaissance Technologies Llc | 67,300 | $414K | Added | Mar 2026 |
| 12 | Vanguard Portfolio Management Llc | 60,583 | $373K | New | Mar 2026 |
| 13 | Morgan Stanley | 46,588 | $336K | Added | Dec 2025 |
| 14 | Nuveen, Llc | 37,451 | $230K | Added | Mar 2026 |
| 15 | Eversource Wealth Advisors, Llc | 4,023 | $174K | Added | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 26,099 | $161K | Added | Mar 2026 |
| 17 | Man Group Plc | 23,699 | $146K | New | Mar 2026 |
| 18 | Acadian Asset Management Llc | 23,484 | $142K | New | Mar 2026 |
| 19 | Twin Focus Capital Partners, Llc | 19,500 | $120K | — | Mar 2026 |
| 20 | Public Employees Retirement System Of Ohio | 13,000 | $80K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$250.1M
Enterprise Value
$125.0M
P/E (TTM)
-1.92x
Forward P/E
—
PEG Ratio
-0.02x
P/B
—
P/S
89.43x
P/FCF
-3.15x
EV/EBITDA
—
Shares Out
26.0M
Financials (TTM)
Revenue
$2.8M
Net Income
-$130.3M
EBITDA
-$86.7M
Free Cash Flow
-$79.4M
Op Cash Flow
-$73.9M
EPS Basic
$-5.02
EPS Diluted
$-5.02
EPS Forward
$-3.29
Gross Margin
100.0%
Op Margin
-3099.9%
Net Margin
-4658.6%
Balance Sheet
Total Assets
$296.4M
Total Liab.
$422.7M
Total Equity
-$126.2M
Cash
$125.1M
LT Debt
$0
Book Value/Sh
$-4.86
Debt/Equity
-0.10x
Current Ratio
8.65
Quick Ratio
8.65
Returns & Growth
ROE
103.2%
ROA
-44.0%
ROIC
-28.4%
Rev Growth YoY
-92.8%
EPS Growth YoY
-67.9%
Price Returns
2W
-8.8%
1M
+21.2%
3M
-0.7%
6M
+0.7%
12M
-21.1%
Technicals
52W High
$13.77
52W Low
$5.84
50d MA
$7.20
200d MA
$7.70
RSI (14)
62.50
ATR (14)
$1.13
Beta
0.56
Avg Volume
358K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$16.00
High
$16.00
Low
$16.00
Median
$16.00
Data updated apr 26, 2026 11:12pm
· Source: financialmodelingprep.com